Cointime

TC BioPharm

company

About

TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors.

  • 51 - 100

Highlights

Total Funding Amount
$16M
Funding Rounds
1
Investors
1
Investments
1

Details

Last Funding Type
Series B
Last Funding Money Raised
$16M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2013
Number Of Employee
51 - 100
Operating Status
Active

TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors. TC BioPharm’s mission is to develop and commercialize innovative cell-based products to treat disease, improving patient health and quality of life.

TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders, including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell, in renal cell cancinoma, non-small cell lung cancer and melanoma patients.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$16M
TC BioPharm has raised a total of $16M in funding over 2 rounds. Their latest funding was raised on Dec 7, 2017 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 7, 2017 Series B $16M 1 Bluebird Bio — Detail

Investments

Number of Investments
Number of Lead Investments
1
0
TC BioPharm has made 1 investments. Their most recent investment was on Dec 15, 2021, when Forethought raised $65M.
Date Company Name
Round Money Raised Industry Lead Investor
Dec 15, 2021 Forethought
Series C $65M Artificial Intelligence —

Investors

Number of Lead Investors
Number of Investors
1
1
TC BioPharm is funded by 1 investors. Bluebird Bio are the most recent investors.
Investor Name Lead Investor Funding Round
Bluebird Bio Yes Series B
Cointime
Content
Company